Serial No.: 08/417,714

FORM PTO-1449								FFICE	ATTY. DOCKE	2026-4124U\$1	08/417.F14				
	INF(DRMATION D	ISCL	osu	RE (CITA	TIO	4		APPLICANT	Kawak	ami And I	Rosenberg	9886	
		(Use several	sheet:	s if ne	ecesso	ary)				FILING DATE	April 5, 1995	C	GROUP [81	09/8/60	
								PAT	ENT D	OCUMENTS					
	MINER ITIAL				DOCUM	MENT N	UMBER	\		DATE	NAME	CLAS	S SUBCLASS	FILING IF APPR	G DAT
5	PH		5	2	6	2	1	7	7	11/16/93	Brown et al.		 		
	/		5	3	4	2	7	7	4	08/31/94	Boon et al.	-			
							FOR	EIGN	PATE	ENT DOCUME	NTS			·	
												CLASS	TRANSLATIO		
_					DOCUN	(ENT N	UMBER			DATE	COUNTRY			YES	N
5	74		0	6	6	8	3	5	0	08/23/95	EPO				
			3	3	4	1	3	6	7	05/24/84	GERMANY (DE)	_			
			2	1	3	3	5	4	3	08/25/84	GB	_			
	•		9	5	2	2	5	6	1	08/24/95	PCT	_			
			9	4	2	3	0	6	7	10/13/94	PCT	_			
7			9	3	1	4	1 ~	8	9	07/22/93	PCT				
		<u> </u>		THE	R DO	CUME	NTS (Includ	ing Au	thor. Tisle, Date	, Pertinent Papers, Et	c.)			
5	TH						ป. (199 ว. 14:1			oding for tumor	antigens recognized by	human c	ytolytic T-lymphocy	ytes*	
	4			Coulie P.G. et al. "A new gene coding on HLA-A2 melanomas", J. Exp Med								ized by au	tologous cytolytic	[lympho	cytes
							ط.: C 3:87-9		and e	xpression of the	gene for the melanome	a associate	ed ME20 antigen. L	ONA and	Cell
							*Iden 4:716-		on of	peptide recogni	ized by five melanoma	-specific b	uman cytotoxic T c	ell lines"	
										e gene codes for 1. 1993; 178:489	an antigen recognized 495.	by autolo	gous cytolytic T ly	mphocyte	€ on
	\bigvee									AGE-3 codes for 179:921-930.	an antigen recognized	on a mel	anoma by autologo	us cytolyt	ic T

Sheet 2 of ATTY, DOCKET NO.: 2026-4124

		
574		Traversari, C., et al.: "A nonapeptide encoded by human gene MAGE-I is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E". J Exp. Med. 1992; 176:1453-1457.
		Cellis, E., et al.: "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptides epitopes". <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1994; 91:2105-2109.
	·	Boon, T.: "Toward a genetic analysis of tumor rejection antigens". Adv. Cancer Res. 1992; 58:177-210.
		Kawakami, Y., et al.; T-cell recognition of human melanoma antigens. J. Immunother. 1993; 14:88-93.
		Bakker, A.B.H., et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor infiltrating lymphocytes. <i>J. Exp. Med.</i> 1994; 179:1005-1009.
		Wölfel, T., et al.: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T. lymphocytes. Eur. J. Immunol. 1994; 24:759-764.
		Adema, G.J., et al.: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-beteb. HMB-50, and HMB-45 are encoded by a single cDNA. Am J. Pathol. 1993; 143:1579-1585.
	·	Kwon, B.S., et al.: A melanocyte-specific gene, Proel 17, maps near the silver coat color locus on mouse chromosom 10 and is in a syntenic region on human chromosome 12. Proc. Natl. Acad. Sci. USA 1991; 88:9228-9232.
		Rosenberg, S.A., et al.: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 1988; 319:1676-1680.
		Kawakami, Y., et al.,: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2. transfected melanomas. J Immunol 1992; 148:638-643.
		Van der Bruggen, et al.: A gene encoding an antigen recognized by cytolytic T. lymphocytes on a human melanoma. Science 1991; 254:1643-1647.
		Falk, K., et al.: "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules." <i>Nature</i> 1991, 351:290-296.
		Kubo, R., et al.: "Definition of specific peptide motifs for four major HLA-A Alleles." Journal of Immunology 1994, 152:3913-3924.
		Parker, K., et al.: "Sequence motifs important for peptide binding to the human MHC class 1 molecule. HLA-A2." 1992, J. Immunol:3580-3587.
		Ruppert, J., et al.: "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules." Cell 1993, 74:929-937.
	·	Storkus, W., et al.: "Identification of human melanoma peptides recognized by class 1 restricted tumor infiltrating T lymphocytes." Journal of Immunology 1993, 151:3719-3727.
		Kawakami, Y., et al.: "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor." <i>Pro. Natl. Acad. Sci. USA</i> 1994, 91:3515-3519.
		Adema, G.J. et al., "Molecular characterization of the melanocyte lineage-specific antigen gp100." Journal of Biological Chemistry 1994, 269:20126-20133.
		EMBL DATABASE ACCESSION NUMBER M32295:26-11-90 Vogel A.: Human KD melanocyte specific secreted glycoprotein MRNA 3'end'
		Kawakami, Y., et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection" PNAS 91:6458-6462 1994
		Kawakami, Y., et al., "Identification of the Immunodominant Peptides of the MART-I Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes" J. Exp. Med. 180:347-352, 1994
		Rivoltini, L., et al., "Induction of Tumor-Reactive CTL from Peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART 1" Journal of Immunology, 1995, 154:2257-2265
7/-		Slingluff, C.L., Jr., et al., "Direct analysis of tumor-associated peptide antigens" Current Opinion in Immunology 1994 6:733-740

Sheet <u>3</u> of ATTY. DOCKET NO.: 2026-4124

554		Cole, D.J., et al., *Characterization of the Functional Specificity of a Cloned T-Cell Receptor Heterodimer Recognizar the MART-1 Melanoma Antigen* Cancer Res. 55:748-752 Feb. 1995
		Cole, D.J., et al., "Identification of MART-1-specific T-Cell Receptors: T Cells Utilizing Distinct T-Cell Receptor Variable and Joining Regions Recognize the Same Tumor Epitope" Cancer Res. 54:5265-5268, 1994
		Castelli, C., et al., "Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8" Cytotoxic T Lymphocytes" J. Exp. Med. 181:363-368 1995
		Sette, A., et al., "Peptide Binding To The Most Frequent HLA-A Class I Alleles Measured By Quantitative Molecular Binding Assays" Molecular Immunology 31:813-822, 1994
		Wölfel, T., et al., "Analysis Of Antigens Recognized On Human Melanoma Cells By A2-Restricted Cytolytic T Lymphocytes (CTL)" Ins. J. Cancer 55:237-244, 1993.
		Wölfel, T., et al., "Isolation Of Naturally Processed Peptides Recognized By Cytolytic Lymphocytes (CTL) On Human Melanoma Cells In Association With HLA-A2.1° Int. J. Cancer 57:413-418, 1994.
		Topalian, S.L., et al., "Human CD4" T Cells Specifically Recognize a Shared Melanoma-Associated Antigen Encoded by the Tyrosinase Gene" PNAS 91:9461-9465, 1994.
		Boël, P., et al., "BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes" <i>Immunity</i> 2:167-175 1995
		Slingluff, C.L., Jr., et al., "Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocyte Is Mediated by at Least Six Shared Peptide Epitopes" Journal of Immunology 150:2955-2963 1993
		GENBANK DATABASE ACCESSION NUMBER M77348 - Human PMEL 17 in RNA - January 8, 1995
		GENBANK DATABASE ACCESSION NUMBER U06654 - Human Differentiation Antigen Melan-A Protein in RNA - July 30, 1994
		GENBANK DATABASE ACCESSION NUMBER U06452 - Human Melanoma Antigen Recognized by T-Cells (MAR7-1) MRNA - June 25, 1994
		GENBANK DATABASE ACCESSION NUMBER \$73003 - GP100 Melanocyte Lineage Specific Antigen / PMELL 7 January 25, 1995
		GENBANK DATABASE ACCESSION NUMBER U01874 - Human ME20 MRNA May 27, 1994
EXAMINER	, Sh	Cuil DATE CONSIDERED 10/24/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-FB-AB20 also form PTO-1449)

Patent and Trademark Office - U.S. DEPARTMENT of COMMER

				~C.
Please type a plus sign (+) inside this box ->	₩ _•	UG 1	f 1	2003

·			, grie	C mplete if Known				
Substitute for for	m 1449A/B/PTO		TAT & TRIC	Application Number	09/898,860			
INFO	RMATION I			Filing Date	July 3, 2001			
	• • • • • • • • • • • • • • • • • • • •			First Named Inventor	Yutaka Kawakami			
STA	TEMENT BY	AP	PLICANI	Group Art Unit	1642			
•	(Use as many sheets	s as ned	cessary)	Examiner Name	Sheela Jitendra Huff			
Sheet	1	of	1	Attorney Docket Number	218748			
Sneet		OI	•	Attorney Docket Number	210/40			

			U.	S. PATENT DOCUMENTS		
		U.S. Patent Do	cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
						
						· · · · · · · · · · · · · · · · · · ·
					<u> </u>	
					REC	EIVE
			 	•	 	
· · · · · ·			-		AUG	1 3 2003
				***************************************	TEOU OF	1775 # 577 188
					JEUH CE	1775 0 5 5 5 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
					·	
			1			

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
SM		wo	92/21767		Bristol Meyers	10-12-92		
, ,								
						_		<u> </u>
								├ ─
!		l		I		·	l	I

Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	lation			
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.					
224		Cohen, Science, 262, 841 (1993)					
		Webster's New Riverside Dictionary, p. 365 (1984)					
		1					

Date Considered **Examiner Signature**

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).